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clinical effectiveness were obtained from published sources. A
12-month time horizon was adopted, with probabilistic sensi-
tivity analysis and threshold analyses conduced to assess the
impact of uncertainty in parameter estimates. RESULTS: Exam-
ples of published cost-effectiveness analyses included troglita-
zone (PPAR activator, withdrawn in 2000 for hepatotoxicity),
and rofecoxib (COX-2 inhibitor, withdrawn in 2004 for cardio-
vascular toxicity). Despite including ADRs in the analyses, both
drugs were deemed cost-effective. The analysis of treatments for
allergic rhinitis revealed that, in fact, chlorpheniramine had a less
favourable risk/beneﬁt ratio than terfenadine, with a mean dif-
ference of 3.5 QALYs per 1000 patients (95% credible interval,
0.3, 7.6). Threshold analysis suggested that it would require the
relative risk of serious injury with terfenadine, compared with
chlorpheniramine, to increase from 45% to 85%, or for the efﬁ-
cacy of terfenadine to reduce from 60% to 34% for the decision
to be reversed. CONCLUSION: The inclusion in economic eval-
uations of ADRs that are deemed too hazardous to warrant
market authorisation by regulators, may lead to counter-intuitive
estimates of cost-effectiveness. This may be the fault of regula-
tors for not adopting decision analytic models, or reﬂect a lack
of risk aversion in economic evaluations. Alternative explana-
tions are explored.
ALLERGY/ASTHMA—Cost Studies
PAA5
ECONOMIC EVALUATION OF SYMBICORT®
(BUDESONIDE/FORMOTEROL) MAINTENANCE AND
RELIEVER THERAPY IN ASTHMA (SMART) COMPARED TO
FIXED DOSE COMBINATION STRATEGIES
Miller B1, FitzGerald JM2
1Axia Research Inc, Hamilton, ON, Canada, 2The Lung Centre,
Vancouver General Hospital,Vancouver, BC, Canada
OBJECTIVES: To compare the cost-effectiveness of budes-
onide/formoterol in a single inhaler used as Maintenance and
Reliever Therapy (SMART) versus ﬁxed-dose ﬂuticasone/salme-
terol (FD) plus as-needed terbutaline reliever or ﬁxed higher-dose
budesonide/formoterol (FHD) plus as-needed terbutaline reliever
in controlling asthma in adults and adolescents. METHODS:
An economic evaluation was conducted based on the results 
of a large (N = 3335) RCT in which health resource utiliza-
tion was prospectively collected. Primary outcome measure-
ments included time to ﬁrst exacerbation and the number of
severe exacerbations. Costs included direct medical costs (physi-
cian/emergency room visits, hospitalizations, asthma drug costs)
and productivity (absenteeism). The time horizon was six-
months which corresponded to the duration of the trial. Prices
were obtained from 2006 Canadian sources. Both health care
(HC) and societal (Soc) perspectives were considered. Determin-
istic univariate sensitivity analyses were conducted. RESULTS:
In the clinical trial, SMART was superior to FD (p < 0.001) and
FHD (p = 0.0048). Exacerbation rates (reported as per patient
per 6 months) were 0.12 for SMART, 0.19 for FD, and 0.16 for
FHD. All treatments provided similar improvements in lung
function, asthma control days and asthma-related quality of life.
From the HC perspective, the mean cost per patient per 6 months
was $583 in the SMART arm versus $867 in the FD arm versus
$737 in the FHD arm. From the Soc perspective, it was $633 for
SMART, $914 for FD and $799 for FHD. SMART was domi-
nant (more effective, less expensive) in the base case analysis
from both the HC and Soc perspectives. The results were robust
under sensitivity testing. CONCLUSION: The SMART strategy
which allows budesonide/formoterol to be used as both mainte-
nance and reliever medication is dominant over a strategy of
ﬁxed dose salmeterol and ﬂuticasone plus as-needed terbutaline
and ﬁxed higher dose budesonide and formoterol plus as-needed
terbutaline.
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ECONOMIC EVALUATION OF A NEW AIRWAY
INFLAMMATION MONITOR IN THE DIAGNOSIS AND
MANAGEMENT OF ASTHMA IN THE US
Berg J, Lindgren P
European Health Economics, Stockholm, Sweden
OBJECTIVES: Fractional exhaled nitric oxide (FENO) is a
marker for the airway inﬂammation underlying asthma. NIOX
is a non-invasive, user-friendly FENO monitor that can be used
in physicians’ ofﬁces to provide immediate information on
patient response to anti-inﬂammatory treatment. The objective
of this study was to assess the cost-effectiveness of NIOX in
asthma diagnosis and management in the US. METHODS: Based
on a literature review, two decision trees were constructed to
capture the different alternatives and consequences in asthma
diagnosis and management, comparing FENO measurement
against standard diagnostics and treatment guidelines. The
impact of asthma management with FENO measurement on
resource use and health outcomes was evaluated over a 1-year
timeframe. A US payer perspective was chosen, using 2006 costs
from standard sources. Effectiveness was measured in quality-
adjusted life-years (QALYs). RESULTS: Asthma diagnosis based
on NIOX results in a cost of $29 per patient, including the cost
of false diagnoses, compared to $49 for standard diagnostics
(spirometry, reversibility testing, bronchoprovocation, sputum
eosinophil count). In mild to severe patients, asthma manage-
ment with FENO measurement instead of spirometry leads to
0.06 QALYs gained and cost-savings of $350 per patient and
year, of which $295 stem from reduced hospitalisations and $5
from lower doses of inhaled corticosteroids (ICS). In a more
severe population, management with NIOX would save $1350
($1250 from hospitalisations and $55 from reduced ICS doses)
and 0.004 QALYs per patient. Based on four visits per year, the
cost of monitoring would be reduced by $50 per patient with
NIOX. CONCLUSION: Asthma diagnosis based on NIOX
alone is less costly and more accurate than standard diagnostic
methods. The use of FENO measurement in treatment decisions
is less costly than asthma management based on standard guide-
lines and provides similar health beneﬁts.
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PHARMACOECONOMIC OUTCOMES OF LEVALBUTEROL
AND RACEMIC ALBUTEROL IN HOSPITALIZED PATIENTS
REQUIRING NEBULIZATION THERAPY (POLARIS)
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1Sepracor Inc, Marlborough, MA, USA, 2Ovation Research Group, San
Francisco, CA, USA
OBJECTIVES: Studies in patients with asthma and COPD have
demonstrated that levalbuterol (LEV) treatment resulted in sig-
niﬁcantly fewer nebulizations and/or decreased total cost of care
compared with racemic albuterol (RAC). This was a prospective,
multicenter, open-label study in patients hospitalized for acute
bronchospasm that evaluated the cost-effectiveness of the two
treatments. METHODS: Patients were randomized to either
LEV 1.25 mg (N = 241) Q8h or RAC 2.5 mg (N = 238), admin-
istered per routine standing hospital order. The primary endpoint
was the total number of nebulizations (scheduled plus rescue)
during hospitalization. Secondary endpoints included length and
cost of hospital stay. Cost-effectiveness (CE) analyses were con-
A111Abstracts
ducted using patient costs from billing records, and three differ-
ent effectiveness measures [all based on a 0 (worst) to 100 (best)
scale]. The primary CE analysis used Subject General Well Being
score (SGWB), which was a general health assessment question.
Two other effectiveness measures were β-mediated treatment
effect (BMTE) and Disease Symptom Assessment (DSA) scores.
RESULTS: LEV patients required fewer total nebulizations
(median 10 vs 12; p = 0.031), and the two groups were not sta-
tistically different with respect to the number of rescue nebu-
lizations, length of hospital stay, and total hospital cost. For the
primary CE analysis, LEV was as effective (70.0 vs 68.3) and
cost $164 less per patient compared with RAC. For CE analy-
ses using BMTE and DSA, LEV was again as effective (86.9 vs
79.0 and 59.2 vs 57.2, respectively) and cost $174 less per
patient. Bootstrap re-sampling analyses found that approxi-
mately 65%–77% of the 10,000 simulations for LEV fell within
the dominant quadrant on a CE plane. CONCLUSION: In this
study, LEV patients required signiﬁcantly fewer total nebuliza-
tions without an increased need for rescue nebulizations. CE
analysis indicated that LEV was at least as effective as RAC with
a $164 savings in costs.
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OBJECTIVES: This was a prospective, randomized, multicenter,
open label study to determine the cost-effectiveness (CE) of lev-
albuterol versus racemic albuterol in patients hospitalized for
acute asthma or COPD; here we present a subset CE analysis
which focuses on quality-adjusted length of stay (QLOS) as a
measure of effectiveness. METHODS: Patients were randomized
to either levalbuterol (n = 241) or racemic albuterol (n = 238).
We conducted an exploratory CE analysis using QLOS, which
was developed to reﬂect the relative rapidity of symptom reso-
lution over the patient’s hospital stay, conceptually similar to Q-
TWiST. A measure of overall HRQoL based on daily responses
to the Subject General Well-Being (SGWB) score was used as the
utility value. An overall value was obtained by calculating the
sum over the time period, resulting in the QLOS score. QLOS
was also calculated for two other effectiveness measures, Disease
Symptom Assessment (DSA) and beta-mediated treatment effects
(BMTE). Hospital charges obtained from billing records 
were converted to costs by applying cost-to-charge ratios. A
cost/QLOS comparison was made between treatment groups.
Sensitivity analyses examined different time periods and mea-
sures of effectiveness. Bootstrap sampling was used to generate
10,000 samples for each analysis. RESULTS: When SGWB was
the effectiveness measure, levalbuterol compared to racemic
albuterol was associated with lower costs ($3676 vs. $3841,
respectively) and slightly better cumulative effectiveness (11.99
vs. 12.68, respectively; lower value better health). Similar results
were observed using other time periods and BMTE as the effec-
tiveness measure. Results from bootstrap sampling showed that,
in the majority of samples, levalbuterol was associated with
better health and lower costs than racemic albuterol. When DSA
was used, racemic albuterol was slightly more effective but more
costly than levalbuterol. CONCLUSION: In this study using
prospectively collected cost data and QLOS scores, levalbuterol
was at least as effective as racemic albuterol, with total costs that
were $165 less.
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A 4-YEAR ASSESSMENT OF SEVERE AND NON-SEVERE
ASTHMA IN A REAL-WORLD SETTING
Bleecker E1,Tashkin D2, Peters S1, Long A3, O’Connor R4,
Parasuraman B5, Boggs R6
1Wake Forest University, Winston-Salem, NC, USA, 2UCLA, Los
Angeles, CA, USA, 3Massachusetts General Hospital, Boston, MA,
USA, 4Sharp Rees-Stealy Medical Group, San Diego, CA, USA,
5AstraZeneca, Wilmington, DE, USA, 6Formerly AstraZeneca,
Wilmington, DE, USA
OBJECTIVES: To examine health outcomes and costs for
patients with severe and non-severe asthma in a managed care
setting over a 4-year period. METHODS: An administrative
claims database (8.8 million lives) was analyzed (June 2000–May
2004). Patients aged ≥12 years with an ICD-9 code for asthma
and ≥2 claims/year for asthma medication were included; those
with other signiﬁcant respiratory conditions were not. Patients
using omalizumab, continuous oral corticosteroids (OCS),
Advair 500/50, or high-dose inhaled corticosteroids in combi-
nation with any other asthma medication were considered 
to have severe asthma. Outcomes in years 2–4 for patients 
with severe asthma in year 1 were compared with those of
patients with non-severe asthma in year 1. Lack of control was
deﬁned as an asthma-related hospitalization or emergency
department (ED) visit, OCS burst for asthma, more than 4 clinic
visits for asthma per year or more than 2 per quarter, or more
than 5 prescriptions for asthma rescue medication per year.
RESULTS: Of 3998 patients identiﬁed (mean age = 41 years,
65% female), 594 (15%) had severe asthma in year 1. Patients
with severe asthma had signiﬁcantly more hospitalizations per
1000 patients per year (7.2 vs 4.3; p < 0.001), ED visits per 1000
patients per year (8.8 vs 6.1; p = 0.004), clinic visits for asthma
per patient per year (2.93 vs 1.98; p < 0.001), asthma costs per
patient per year ($1331 vs $817; p < 0.001), and lack of control
events per 1000 patients per year (547 vs 462; p < 0.001) than
patients with non-severe asthma. CONCLUSION: Patients with
severe asthma used signiﬁcantly more health care resources than
patients with non-severe asthma. In addition, a signiﬁcant
number of patients in both groups met the deﬁnition for lack of
control.
PAA10
ALLERGY IMMUNOTHERAPY: PATTERNS AND OUTCOMES OF
CARE FOR ALLERGIC RHINITIS
Hankin C1, Cox L2,Wang Z1, Bronstone A1
1BioMedEcon, Moss Beach, CA, USA, 2University of Miami, Ft.
Lauderdale, FL, USA
OBJECTIVES: To examine patterns and economic outcomes of
allergy immunotherapy (IT) care among children with allergic
rhinitis (AR). METHODS: We examined the 1997–2004 Florida
Medicaid dataset to identify children (<18 years) who received
an AR diagnosis and IT. Those receiving IT who were continu-
ously enrolled and had data ≥4 years following and ≥1 year prior
to initial AR diagnosis were included in clinical and economic
subanalyses. RESULTS: There were 104,963 children diagnosed
with AR; 5532 (5.3%) received IT. Mean age at IT initiation was
8.2 years (SD 3.5). Compared to those with AR who did not
receive IT, children who received IT were signiﬁcantly older
(mean age 7.7 versus 7.0, SD 3.6, p = 0.001). Signiﬁcantly less
patients receiving IT were female or Caucasian (p ≤ 0.001). The
average number of IT administrations was 22 (SD 27.0); approx-
imately half of patients (45.2%) received less than 10 IT admin-
istrations. Average treatment duration was 1 year (SD 15.8
months); more than half (51.2%) of patients received IT for less
than 6 months, and only 1 in 12 patients (8.7%) completed the
